(Q48967106)

17 February 2018

title

Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients. (English)

1 reference

17 February 2018

0 references

1 reference

Rösler N

1

1 reference

17 February 2018

Wichart I

series ordinal

2

1 reference

17 February 2018

Jellinger KA

series ordinal

3

1 reference

17 February 2018

language of work or name

English

0 references

publication date

1 February 2001

1 reference

17 February 2018

Acta Neurologica Scandinavica

published in

1 reference

17 February 2018

volume

103

1 reference

17 February 2018

issue

2

1 reference

17 February 2018

page(s)

126-130

1 reference

17 February 2018

Clinicopathological analysis of dementia disorders in the elderly.

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

Neuroimmune mechanisms in Alzheimer disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

7 January 2021

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor rece

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

7 January 2021

Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

7 January 2021

On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

7 January 2021

Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

7 January 2021

Serum levels of interleukin-6 and acute phase responses

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2001.103002126.X

7 January 2021

10.1034/J.1600-0404.2001.103002126.X

Identifiers

DOI

1 reference

17 February 2018

PubMed ID

11227132

1 reference

17 February 2018